These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 8095399

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
    Nicoletti MI, Lucchini V, D'Incalci M, Giavazzi R.
    Eur J Cancer; 1994; 30A(5):691-6. PubMed ID: 7915909
    [Abstract] [Full Text] [Related]

  • 3. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.
    Clin Cancer Res; 2003 Aug 15; 9(9):3476-85. PubMed ID: 12960140
    [Abstract] [Full Text] [Related]

  • 4. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy.
    Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, Mantovani A, D'Incalci M, Mangioni C, Giavazzi R.
    Int J Cancer; 1989 Sep 15; 44(3):494-500. PubMed ID: 2777413
    [Abstract] [Full Text] [Related]

  • 5. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
    Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendriks H, D'Incalci M, Faircloth G, Giavazzi R.
    Clin Cancer Res; 1998 Aug 15; 4(8):1977-83. PubMed ID: 9717828
    [Abstract] [Full Text] [Related]

  • 6. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G.
    Clin Cancer Res; 1998 Apr 15; 4(4):985-92. PubMed ID: 9563894
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
    Boven E, Venema-Gaberscek E, Erkelens CA, Bissery MC, Pinedo HM.
    Ann Oncol; 1993 Apr 15; 4(4):321-4. PubMed ID: 8100146
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
    Chou TC, Dong H, Zhang X, Tong WP, Danishefsky SJ.
    Cancer Res; 2005 Oct 15; 65(20):9445-54. PubMed ID: 16230408
    [Abstract] [Full Text] [Related]

  • 9. Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.
    Dunn TA, Grünwald V, Bokemeyer C, Casper J.
    Invest New Drugs; 1997 Oct 15; 15(2):91-8. PubMed ID: 9220287
    [Abstract] [Full Text] [Related]

  • 10. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
    Auzenne E, Donato NJ, Li C, Leroux E, Price RE, Farquhar D, Klostergaard J.
    Clin Cancer Res; 2002 Feb 15; 8(2):573-81. PubMed ID: 11839679
    [Abstract] [Full Text] [Related]

  • 11. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.
    Burbridge MF, Kraus-Berthier L, Naze M, Pierre A, Atassi G, Guilbaud N.
    Int J Oncol; 1999 Dec 15; 15(6):1155-62. PubMed ID: 10568822
    [Abstract] [Full Text] [Related]

  • 12. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease.
    Masazza G, Lucchini V, Tomasoni A, Peccatori F, Lampasona V, Giudici G, Mangioni C, Biondi A, Giavazzi R.
    Cancer Res; 1991 Dec 01; 51(23 Pt 1):6358-62. PubMed ID: 1933898
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T, Vance R, Puneky L, Khansur T.
    Gynecol Oncol; 1994 Dec 01; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X, Lu M, Li C, Deng S, Li M.
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul 01; 49(7):517-22. PubMed ID: 25327734
    [Abstract] [Full Text] [Related]

  • 16. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts.
    Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ.
    Int J Cancer; 1997 Mar 28; 71(1):103-7. PubMed ID: 9096672
    [Abstract] [Full Text] [Related]

  • 17. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I, Furukawa H, Hayashi H, Nakamura K, Inokuchi M, Nakagawara H, Miyashita T, Tajima H, Takamura H, Ninomiya I, Fujimura T, Masakazu Y, Hirakawa K, Ohta T.
    Oncol Rep; 2014 Jul 28; 32(1):89-96. PubMed ID: 24859429
    [Abstract] [Full Text] [Related]

  • 18. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Bizzaro F, Falcetta F, D'Agostini E, Decio A, Minoli L, Erba E, Alessandro Peccatori F, Scanziani E, Colombo N, Zucchetti M, Bani MR, Ubezio P, Giavazzi R.
    Int J Cancer; 2018 Nov 01; 143(9):2187-2199. PubMed ID: 29752717
    [Abstract] [Full Text] [Related]

  • 19. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, Nagata I.
    Jpn J Clin Oncol; 2000 Oct 01; 30(10):446-9. PubMed ID: 11185891
    [Abstract] [Full Text] [Related]

  • 20. Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response.
    Klostergaard J, Auzenne E, Ghosh S, Farquhar D, Rivera B, Price RE.
    Int J Gynecol Cancer; 2006 Oct 01; 16 Suppl 1():111-7. PubMed ID: 16515577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.